Avenue Therapeutics (ATXI) Competitors

$0.52 -0.13 (-20.00%)

As of 02:52 PM Eastern

ATXI vs. PCSA, TNFA, XBIO, BCAB, and BMRA

Should you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Heatwurx (PCSA), TNF Pharmaceuticals (TNFA), Xenetic Biosciences (XBIO), BioAtla (BCAB), and Biomerica (BMRA). These companies are all part of the "pharmaceutical products" industry.

How does Avenue Therapeutics compare to Heatwurx?

Avenue Therapeutics (NASDAQ:ATXI) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

: Avenue Therapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500. Comparatively, Heatwurx has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.
: In the previous week, Heatwurx had 5 more articles in the media than Avenue Therapeutics. MarketBeat recorded 5 mentions for Heatwurx and 0 mentions for Avenue Therapeutics. Heatwurx's average media sentiment score of 1.00 beat Avenue Therapeutics' score of 0.00 indicating that Heatwurx is being referred to more favorably in the news media.
Company Overall Sentiment
Avenue Therapeutics Neutral
Heatwurx Positive
: Avenue Therapeutics is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avenue Therapeutics N/A N/A -$10.38M -$0.94 N/A
Heatwurx N/A N/A -$13.56M -$34.00 N/A
: Heatwurx has a consensus price target of $25.00, indicating a potential upside of 839.85%. Given Heatwurx's stronger consensus rating and higher probable upside, analysts plainly believe Heatwurx is more favorable than Avenue Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Heatwurx
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Heatwurx's return on equity of -257.81% beat Avenue Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Avenue Therapeutics N/A -471.57% -296.50%
Heatwurx N/A -257.81% -191.10%
: 17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Heatwurx shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Comparatively, 2.4% of Heatwurx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
Heatwurx	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.94	N/A
Heatwurx	N/A	N/A	-$13.56M	-$34.00	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Heatwurx	N/A	-257.81%	-191.10%

Summary

Heatwurx beats Avenue Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Avenue Therapeutics compare to TNF Pharmaceuticals?

Avenue Therapeutics (NASDAQ:ATXI) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

: 17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Avenue Therapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500. Comparatively, TNF Pharmaceuticals has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
TNF Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: TNF Pharmaceuticals' return on equity of -69.21% beat Avenue Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Avenue Therapeutics N/A -471.57% -296.50%
TNF Pharmaceuticals N/A -69.21% -33.98%
: Avenue Therapeutics is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avenue Therapeutics N/A N/A -$10.38M -$0.94 N/A
TNF Pharmaceuticals N/A N/A -$23.36M -$231.00 N/A
: In the previous week, Avenue Therapeutics' average media sentiment score of 0.00 equaled TNF Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
Avenue Therapeutics Neutral
TNF Pharmaceuticals Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.94	N/A
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

Company	Overall Sentiment
Avenue Therapeutics	Neutral
TNF Pharmaceuticals	Neutral

Summary

Avenue Therapeutics beats TNF Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Avenue Therapeutics compare to Xenetic Biosciences?

Xenetic Biosciences (NASDAQ:XBIO) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

: 15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Xenetic Biosciences has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xenetic Biosciences
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Avenue Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Avenue Therapeutics has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -90.09%. Xenetic Biosciences' return on equity of -51.27% beat Avenue Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Xenetic Biosciences -90.09% -51.27% -43.63%
Avenue Therapeutics N/A -471.57% -296.50%
: Xenetic Biosciences has higher revenue and earnings than Avenue Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xenetic Biosciences $2.98M 2.38 -$2.68M -$1.59 N/A
Avenue Therapeutics N/A N/A -$10.38M -$0.94 N/A
: In the previous week, Xenetic Biosciences' average media sentiment score of 1.32 beat Avenue Therapeutics' score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the media.
Company Overall Sentiment
Xenetic Biosciences Positive
Avenue Therapeutics Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-90.09%	-51.27%	-43.63%
Avenue Therapeutics	N/A	-471.57%	-296.50%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98M	2.38	-$2.68M	-$1.59	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.94	N/A

Company	Overall Sentiment
Xenetic Biosciences	Positive
Avenue Therapeutics	Neutral

Summary

Xenetic Biosciences beats Avenue Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Avenue Therapeutics compare to BioAtla?

BioAtla (NASDAQ:BCAB) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

: In the previous week, BioAtla's average media sentiment score of 0.00 equaled Avenue Therapeutics'average media sentiment score.
Company Overall Sentiment
BioAtla Neutral
Avenue Therapeutics Neutral
: Avenue Therapeutics has lower revenue, but higher earnings than BioAtla. Avenue Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioAtla $2M 3.64 -$59.61M -$50.50 N/A
Avenue Therapeutics N/A N/A -$10.38M -$0.94 N/A
: BioAtla has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500.
: 77.2% of BioAtla shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 11.8% of BioAtla shares are owned by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: BioAtla's return on equity of 0.00% beat Avenue Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
BioAtla N/A N/A -257.22%
Avenue Therapeutics N/A -471.57% -296.50%
: BioAtla presently has a consensus price target of $200.00, indicating a potential upside of 4,466.21%. Given BioAtla's stronger consensus rating and higher possible upside, research analysts clearly believe BioAtla is more favorable than Avenue Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioAtla
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Avenue Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Overall Sentiment
BioAtla	Neutral
Avenue Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.64	-$59.61M	-$50.50	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.94	N/A

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-257.22%
Avenue Therapeutics	N/A	-471.57%	-296.50%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

BioAtla beats Avenue Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Avenue Therapeutics compare to Biomerica?

Avenue Therapeutics (NASDAQ:ATXI) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

: Biomerica has a consensus target price of $9.00, indicating a potential upside of 306.50%. Given Biomerica's stronger consensus rating and higher probable upside, analysts plainly believe Biomerica is more favorable than Avenue Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Biomerica
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: 17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 22.3% of Biomerica shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Comparatively, 18.0% of Biomerica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: Avenue Therapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.
: Biomerica has higher revenue and earnings than Avenue Therapeutics. Biomerica is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avenue Therapeutics N/A N/A -$10.38M -$0.94 N/A
Biomerica $4.33M 1.58 -$4.97M -$0.89 N/A
: Avenue Therapeutics has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Biomerica's return on equity of -98.14% beat Avenue Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Avenue Therapeutics N/A -471.57% -296.50%
Biomerica -96.49% -98.14% -70.42%
: In the previous week, Biomerica had 3 more articles in the media than Avenue Therapeutics. MarketBeat recorded 3 mentions for Biomerica and 0 mentions for Avenue Therapeutics. Biomerica's average media sentiment score of 0.27 beat Avenue Therapeutics' score of 0.00 indicating that Biomerica is being referred to more favorably in the news media.
Company Overall Sentiment
Avenue Therapeutics Neutral
Biomerica Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.94	N/A
Biomerica	$4.33M	1.58	-$4.97M	-$0.89	N/A

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Biomerica	-96.49%	-98.14%	-70.42%

Company	Overall Sentiment
Avenue Therapeutics	Neutral
Biomerica	Neutral

Summary

Biomerica beats Avenue Therapeutics on 12 of the 14 factors compared between the two stocks.

Get Avenue Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATXI vs. The Competition

Export

Metric	Avenue Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.71M	$889.45M	$6.25B	$11.87B
Dividend Yield	N/A	4.84%	2.73%	5.21%
P/E Ratio	0.03	1.71	29.04	28.48
Price / Sales	N/A	120.50	476.48	60.89
Price / Cash	N/A	20.07	27.62	36.52
Price / Book	0.27	7.60	9.67	6.67
Net Income	-$10.38M	-$4.80M	$3.55B	$332.64M
7 Day Performance	-5.45%	-0.05%	1.70%	2.01%
1 Month Performance	48.57%	5.50%	5.62%	9.19%
1 Year Performance	125.99%	30.96%	34.42%	39.59%

Avenue Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATXI Avenue Therapeutics	N/A	$0.52 -20.0%	N/A	N/A	$1.71M	N/A	0.03	4	Gap Down
PCSA Heatwurx	3.142 of 5 stars	$2.65 -7.0%	$25.00 +843.4%	N/A	$7.05M	N/A	N/A	20
TNFA TNF Pharmaceuticals	N/A	$3.78 -4.5%	N/A	N/A	$6.98M	N/A	N/A	6	Gap Down
XBIO Xenetic Biosciences	1.098 of 5 stars	$3.01 -4.0%	N/A	N/A	$6.88M	$2.98M	N/A	4	Positive News Upcoming Earnings Gap Down
BCAB BioAtla	2.629 of 5 stars	$4.04 -6.0%	$200.00 +4,850.5%	N/A	$6.69M	$2M	N/A	60	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATXI) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avenue Therapeutics (ATXI) Competitors

ATXI vs. PCSA, TNFA, XBIO, BCAB, and BMRA

How does Avenue Therapeutics compare to Heatwurx?

Summary

How does Avenue Therapeutics compare to TNF Pharmaceuticals?

Summary

How does Avenue Therapeutics compare to Xenetic Biosciences?

Summary

How does Avenue Therapeutics compare to BioAtla?

Summary

How does Avenue Therapeutics compare to Biomerica?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI vs. The Competition

Avenue Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avenue Therapeutics (ATXI) Competitors

ATXI vs. PCSA, TNFA, XBIO, BCAB, and BMRA

How does Avenue Therapeutics compare to Heatwurx?

Summary

How does Avenue Therapeutics compare to TNF Pharmaceuticals?

Summary

How does Avenue Therapeutics compare to Xenetic Biosciences?

Summary

How does Avenue Therapeutics compare to BioAtla?

Summary

How does Avenue Therapeutics compare to Biomerica?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI vs. The Competition

Avenue Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools